Mohamed Hamdani Selected Research

pegcetacoplan

1/2021	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
1/2021	Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
1/2020	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mohamed Hamdani Research Topics

Disease

7	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 05/2014 - 08/2009
2	Headache (Headaches) 01/2021 - 07/2012
2	Geographic Atrophy 01/2021 - 01/2020
2	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2019 - 10/2017
1	Friedreich Ataxia (Friedreich's Ataxia) 02/2024
1	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2024
1	Injection Site Reaction 01/2021
1	Chronic Disease (Chronic Diseases) 01/2021
1	Diarrhea 01/2021
1	Fatigue 01/2021
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2021
1	Hemolysis 01/2021
1	Weight Loss (Weight Reduction) 11/2020
1	Brain Injuries (Brain Injury) 01/2020
1	Endophthalmitis (Ophthalmia) 01/2020
1	Macular Degeneration (Age-Related Maculopathy) 01/2020
1	Hemorrhage 01/2018
1	Leukemia 01/2018
1	Neoplasms (Cancer) 01/2018
1	Essential Thrombocythemia 01/2018
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2018
1	Primary Myelofibrosis (Myelosclerosis) 01/2018
1	Infections 10/2017
1	Deglutition Disorders (Dysphagia) 01/2017
1	Separation Anxiety (Separation Anxiety Disorder) 01/2017
1	Social Phobia 01/2017
1	Eosinophilic Esophagitis 01/2017
1	Anxiety Disorders (Anxiety Disorder) 01/2017
1	Eosinophilia 01/2017
1	Sleep Initiation and Maintenance Disorders (Insomnia) 07/2012
1	Respiratory Tract Infections (Respiratory Tract Infection) 07/2012

Drug/Important Bio-Agent (IBA)

7	Lisdexamfetamine Dimesylate FDA Link 05/2014 - 08/2009
3	pegcetacoplanIBA 01/2021 - 01/2020
2	Complement C3 (C3 Complement)IBA 01/2021 - 01/2020
2	Insulin-Like PeptidesIBA 01/2019 - 10/2017
1	FrataxinIBA 02/2024
1	Peptides (Polypeptides)IBA 01/2021
1	salicylhydroxamic acid (SHAM)IBA 01/2021
1	eculizumab FDA Link 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Stainless Steel (Steel, Stainless)IBA 11/2020
1	Benzoic Acid (Potassium Benzoate)FDA Link 11/2020
1	protocatechuic acidIBA 11/2020
1	4-hydroxybenzoic acid (p-hydroxybenzoate)IBA 11/2020
1	cupric sulfide (CuS)IBA 01/2020
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	lifitegrastIBA 01/2018
1	anagrelide (Agrylin)FDA LinkGeneric 01/2018
1	SteroidsIBA 01/2017
1	SuspensionsIBA 01/2017
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2017
1	Guanfacine (Tenex)FDA LinkGeneric 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017
1	Budesonide (Pulmicort)FDA LinkGeneric 01/2017

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2018
1	Intravenous Infusions 10/2017
1	Off-Label Use 01/2017
1	Aftercare (After-Treatment) 01/2017